Emerging drugs for levodopa-induced dyskinesia

Bibliography

• Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47:S2-9
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9
   PubMed Web of Science ®Google Scholar
• Kumar N, Van Gerpen JA, Bower JH, et al. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Mov Disord 2005;20:342-4
   PubMed Web of Science ®Google Scholar
• Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson’s disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312
   PubMed Web of Science ®Google Scholar
• Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12:956-63
   PubMed Web of Science ®Google Scholar
• Annic A, Devos D, Seguy D, et al. Continuous dopaminergic stimulation by Duodopa in advanced Parkinson’s disease: efficacy and safety. Rev Neurol 2009;165:718-27
   PubMedGoogle Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-9
   PubMed Web of Science ®Google Scholar
• Fernandez H, Krueger R, Slevin J, et al. Long-term safety and maintenance of efficacy from an open-label extension of the double-blind pivotal study of levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson’s disease patients. [abstract]. Neurology 2014;82(Suppl 10):P7.081
   Google Scholar
• Antonini A, Yegin A, Preda C, et al. Global long-term registry on efficacy and safety of DUODOPA in patients with advanced Parkinson’s disease in routine care (GLORIA): 12-month interim findings. [abstract]. Neurology 2014;82(Suppl 10):S7.005
   Google Scholar
• Antonini A, Fung V, Boyd J, et al. Changes in troublesome dyskinesia and its relationship with dose in advanced parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion. [abstract]. Neurology 2014;82(Suppl 10):P7.071
   Google Scholar
• Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21:S290-304
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26:S2-41
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-91
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53
   PubMed Web of Science ®Google Scholar
• Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-17
   PubMed Web of Science ®Google Scholar
• Holloway R, Marek K, Biglan K, et al. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009;66:563-70
   PubMed Web of Science ®Google Scholar
• Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2008(2):CD006564
   PubMed Web of Science ®Google Scholar
• Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness and dopamine agonists in Parkinson’s disease. Mov Disord 2003;18:659-67
   PubMed Web of Science ®Google Scholar
• Stocchi F, Giorgi L, Hunter B, et al. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord 2011;26:1259-65
   PubMed Web of Science ®Google Scholar
• Study NCT01494532. clinicaltrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01494532?term=ropinirole&recr=Open&rank=3 [Last accessed 9 August 2014]
   Google Scholar
• Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011;77:767-74
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R, et al. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:1262-7
   PubMed Web of Science ®Google Scholar
• Elmer LW, Surmann E, Boroojerdi B, et al. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: a prospective, open-label extension study. Parkinsonism Relat Disord 2012;18:488-93
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Boroojerdi B, Surmann E, et al. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm 2013;120:1069-81
   PubMed Web of Science ®Google Scholar
• Zhou CQ, Lou JH, Zhang YP, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson’s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther 2014;20:368-76
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011;258:579-85
   PubMed Web of Science ®Google Scholar
• Drapier S, Gillioz AS, Leray E, et al. Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord 2012;18:40-4
   PubMed Web of Science ®Google Scholar
• Rambour M, Moreau C, Devos D, et al. Continuous subcutaneous infusion of apomorphine in Parkinson’s disease: retrospective analysis of a series of 81 patients. Rev Neurol (Paris) 2014;170:205-15
   PubMed Web of Science ®Google Scholar
• Tyne HL, Parsons J, Sinnott A, et al. A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease. J Neurol 2004;251:1370-4
   PubMed Web of Science ®Google Scholar
• Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2004(4):CD004554
   PubMedGoogle Scholar
• Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27
   PubMed Web of Science ®Google Scholar
• Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-12
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75:141-3
   PubMed Web of Science ®Google Scholar
• Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 2010;25:1357-63
   PubMed Web of Science ®Google Scholar
• Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1991;54:376-7
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. J Clin Invest 2014;124(3):1340-9
   PubMed Web of Science ®Google Scholar
• Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004;62:381-8
   PubMed Web of Science ®Google Scholar
• Mazzucchi S, Frosini D, Unti E, et al. Can serotoninergic antidepressants prevent or delay the development of L-dopa induced dyskinesias in PD patients? [abstract]. Movement Disord 2013;28(Suppl 1):611
   Google Scholar
• Durif F, Vidailhet M, Bonnet AM, et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-8
   PubMed Web of Science ®Google Scholar
• Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 2006;29:148-53
   PubMed Web of Science ®Google Scholar
• Wong KK, Alty JE, Goy AG, et al. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson’s disease. Mov Disord 2011;26:1552-5
   PubMed Web of Science ®Google Scholar
• Stathis P, Konitsiotis S, Tagaris G, et al. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2011;26:264-70
   PubMed Web of Science ®Google Scholar
• Wolz M, Lohle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm 2010;117:1279-86
   PubMed Web of Science ®Google Scholar
• Bermejo PE, Anciones B. A review of the use of zonisamide in Parkinson’s disease. Ther Adv Neurol Disord 2009;2:313-17
   PubMedGoogle Scholar
• Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007;68:45-50
   PubMed Web of Science ®Google Scholar
• Murata M, Hasegawa K, Fukasaka J, et al. The Japan Zonisamide on PD Study Group. Zonisamide improves wearing-off in Parkinson’s disease: a nation-wide randomized, double-blind study(Abstract). Mov Disord 2013;28(Suppl 1):395
   Google Scholar
• Halje P, Tamtè M, Richter U, et al. Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J Neurosci 2012;32:16541-51
   PubMed Web of Science ®Google Scholar
• Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol 2010;9:1106-17
   PubMed Web of Science ®Google Scholar
• Cenci MA. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 2007;30(5):236-43
   PubMed Web of Science ®Google Scholar
• Di Monte DA, McCormack A, Petzinger G, et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 2000;15:459-66
   PubMed Web of Science ®Google Scholar
• Guigoni C, Dovero S, Aubert I, et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 2005;22:283-7
   PubMed Web of Science ®Google Scholar
• Linazasoro G, Van Blercom N, Bergaretxe A, et al. Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study. Clin Neuropharmacol 2009;32:326-9
   PubMed Web of Science ®Google Scholar
• Tanaka H, Kannari K, Maeda T, et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999;10(3):631-4
   PubMed Web of Science ®Google Scholar
• Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-dopa-induced dyskinesia. J Neurochem 2006;99:381-92
   PubMed Web of Science ®Google Scholar
• Carta M, Carlsson T, Kirik D, et al. Dopamine released from 5-HT terminals is the cause of L-dopa-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-33
   PubMed Web of Science ®Google Scholar
• Munoz A, Li Q, Gardoni F, et al. Combined 5-ht1a and 5-ht1b receptor agonists for the treatment of l-dopa-induced dyskinesia. Brain 2008;131:3380-94
   PubMed Web of Science ®Google Scholar
• AccuformR drug delivery. Depomed.com – Technology Depomed, inc. Available from: http://www.depomed.com/technology [Last accessed 9 August 2014]
   Google Scholar
• Intec Pharma – Accordion Pill™. Intec Pharma Ltd. 2008. Available from: http://www.intecpharma.com/accordion-pill.html [Last accessed 9 August 2014]
   Google Scholar
• Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005;20:919-31
   PubMed Web of Science ®Google Scholar
• Fox S. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs 2013;73:1405-15
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Koprich JB, et al. The pharmacology of l-dopa-induced dyskinesia in parkinson’s disease. Pharmacol Rev 2013;65:171-222
   PubMed Web of Science ®Google Scholar
• Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s disease. Mov Disord 2011;26:2246-52
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346-56
   PubMed Web of Science ®Google Scholar
• Depomed announces initiation of phase 2 clinical study in Parkinson’s disease. Moretti AJ, Depomed, inc. 2012. Available from: http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irolnewsArticle&ID=1652094&highlight=dm-1992 [Last accessed 9 August 2014]
   Google Scholar
• Depomed reports top line data for phase 2 study in Parkinson’s disease. Moretti AJ, Depomed, inc. 2012. Available from: http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irolnewsArticle&ID=1755781&highlight= [Last accessed 9 August 2014]
   Google Scholar
• Metman LV, Stover N, Chen C, et al. Improved Motor performance associated with smoother levodopa time-concentration profiles with dm-1992, a gastroretentive, extended-release carbidopa/levodopa tablet, in patients with advanced Parkinson’s disease. (Abstract). Neurology 2014;82(Suppl 10):P7.08269
   Google Scholar
• LeWitt P, Friedman H, Giladi N, et al. Sustained-release carbidopa-levodopa (accordion pill) in patients with advanced Parkinson’s disease: Pharmacokinetic and clinical experience [abstract]. Mov Disord 2013;28(Suppl 1):499
   Google Scholar
• Freed MI, Grosset DG, Worth PF, et al. Rapid levodopa augmentation following inhaled CVT-301 results in rapid improvement in motor response when administered to PD patients in the OFF state. [abstract]. Neurology 2014;82(Suppl 10):S7.007
   Google Scholar
• Rascol O, Bronzova J, Hauser RA, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012;18:370-6
   PubMed Web of Science ®Google Scholar
• Stocchi F, Ruggieri S, Vacca L, et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 2002;125:2058-66
   PubMed Web of Science ®Google Scholar
• Study NCT00408915. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00408915?term=lisuride&rank=1 [Last accessed 9 August 2014]
   Google Scholar
• Study NCT01023282. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01023282?term=acr325&rank=1 [Last accessed 9 August 2014]
   Google Scholar
• Ordopidine (ACR325). NeuroSearch. Available from: http://neurosearch.com/Default.aspx?ID=8268 [Last accessed 9 August 2014]
   Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 2014;29:229-37
   PubMed Web of Science ®Google Scholar
• Pahwa R, Tanner C, Hauser R, et al. Safety and efficacy study of ADS-5102 (Amantadine HCl) extended release capsules in levodopa-induced dyskinesia (EASED Study). [abstract]. Neurology 2014;82(Suppl 10):P4.053
   Google Scholar
• Verhagen Metman L, Del Dotto P, Natte R, et al. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson’s disease. Neurology 1998;51:203-6
   PubMed Web of Science ®Google Scholar
• Study NCT01767129. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01767129?term=avp-923&rank=2 [Last accessed 9 August 2014]
   Google Scholar
• Study NCT00607451. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00607451?term=neu-120&rank=1 [Last accessed 9 August 2014]
   Google Scholar
• Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson’s disease. Mov Disord 2012;27:284-8
   PubMed Web of Science ®Google Scholar
• Study NCT01789047. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01789047?term=topiramate+amantadine&rank=2 [Last accessed 9 August 2014]
   Google Scholar
• Study NCT00036296. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00036296?term=talampanel&rank=6 [Last accessed 9 August 2014]
   Google Scholar
• Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-50
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013;28:1838-46
   PubMed Web of Science ®Google Scholar
• Tison F, Durif F, Corvol JC, et al. Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mglur5 negative allosteric modulator (NAM) in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID) [abstract]). Neurology 2013;80(Suppl 1):S23.004
   Google Scholar
• Lewitt PA, Hauser RA, Lu M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012;79:163-9
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63:295-302
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70:2233-40
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T; Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord 2013;28:1138-41
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Kieburtz K, et al. A phase 2, placebo-controlled, randomized, doubleblind trial of tozadenant (SYN-115) in patients with Parkinson’s disease with wearing-off fluctuations on levodopa [abstract]. J Nuro Sci 2013;333(Suppl 1):e119
   Google Scholar
• Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011;10:221-9
   PubMed Web of Science ®Google Scholar
• Corporate news. Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine. Merck & Co, Inc. 2013. Available from: http://www.mercknewsroom.com/press-release/research-and-development-news/merckprovides-update-phase-iii-clinical-program-prelade [Last accessed 9 August 2014]
   Google Scholar
• Study NCT01937078. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01937078?term=famotidine&rank=13 [Last accessed 9 August 2014]
   Google Scholar
• Trial ACTRN12610000765022. Australian New Zealand Clinical Trials Registry anzctr.org.au. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335910 [Last accessed 9 August 2014]
   Google Scholar
• Study NCT01474421. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01474421?term=aqw051&rank=3 [Last accessed 9 August 2014]
   Google Scholar
• Neuraltus pharmaceuticals reports clinical results from phase 1/2 NP002 Study in the treatment of dyskinesias resulting from levodopa therapy for Parkinson’s disease. Neuraltus Pharmaceuticals, inc. 2010. Available from: http://www.neuraltus.com/pages/news_rel12_03_10.html [Last accessed 9 August 2014]
   Google Scholar
• Pacchetti C, Albani G, Martignoni E, et al. "Off" painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord 1995;10:333-6
   PubMed Web of Science ®Google Scholar
• Espay AJ, Vaughan JE, Shukla R, et al. Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson’s disease: unfavorable risk-benefit ratio. Mov Disord 2011;26:913-14
   PubMed Web of Science ®Google Scholar
• Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord 2007;22:179-86
   PubMed Web of Science ®Google Scholar
• Rascol O, Damier P, Goetz CG, et al. A large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of l-dopa-induced-dyskinesia associated with PD: the Paddy-1 study. Mov Disord 2006;21:S492-3
   PubMed Web of Science ®Google Scholar